Related Experiment Video
Updated: Jun 3, 2026
05:41
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Thiopurine immunomodulators in ulcerative colitis: moving forward with current evidence
Richard J La Nauze1, Miles P Sparrow
1Department of Gastroenterology and Hepatology, The Alfred Hospital, Melbourne, Australia.
Current Drug Targets
|April 7, 2011
Summary
Thiopurine immunomodulators are key for ulcerative colitis (UC) patients needing more than aminosalicylates. This review covers their efficacy, safety, and role in achieving remission and healing.
Area of Science:
- Gastroenterology and Immunology
- Pharmacology of Inflammatory Bowel Disease
Background:
- Ulcerative colitis (UC) treatment aims for corticosteroid-free remission to prevent complications like colorectal cancer.
- Thiopurine immunomodulators are a primary therapy for patients unresponsive to aminosalicylates or requiring frequent corticosteroids.
Purpose of the Study:
- To review the evidence supporting thiopurine use in achieving UC treatment goals.
- To discuss safety concerns, including lymphoproliferative disease risks and dosage optimization.
- To explore the role of thiopurines in mucosal healing and altering UC's natural history.
Main Methods:
- Literature review of current evidence on thiopurine efficacy and safety in ulcerative colitis.
- Analysis of recent studies on risk factors, dosage strategies, and long-term outcomes.
Main Results:
- Thiopurines demonstrate a role in inducing and maintaining remission in specific UC patient populations.
- Safety considerations, including potential risks like lymphoproliferative disease, require careful monitoring.
- Emerging data suggests thiopurines may contribute to mucosal healing and improve long-term disease outcomes.
Conclusions:
- Thiopurines remain an important therapeutic option for moderate-to-severe ulcerative colitis.
- Balancing efficacy with safety, including personalized dosage, is crucial for optimal patient management.
- Further research is needed to fully elucidate the impact of thiopurines on UC's natural history and mucosal healing.
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:29Drugs for Treatment of Ulcerative Colitis in IBD
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation.
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...